抗肿瘤药物的治疗药物监测研究  

Review of therapeutic drug monitoring of anticancer drugs

作　　者：王晶 李雅倩 周于禄[1] 张曦[2] 裴奇[1,3] FENG Xin-ying;WU Yun-jiao;LI Jia-peng;YANG Chang-qing;ZHAO Li-bo(Department of Pharmacy,The Third Xiartgya Hospital of Central South University,Changsha 410013,China;Depanment of Oncology,The Third Xiartgya Hospital of Central South University,Changsha 410013,China;Center of Clinical Pharmacology,The Third Xiartgya Hospital of Central South University,Changsha 410013,China)

机构地区：[1]中南大学湘雅三医院药学部,长沙410013 [2]中南大学湘雅三医院肿瘤科,长沙410013 [3]中南大学湘雅三医院临床药理中心,长沙410013

出　　处：《中国临床药理学杂志》2018年第24期2889-2893,共5页The Chinese Journal of Clinical Pharmacology

基　　金：湖南省自然科学基金资助项目(2017JJ3464)

摘　　要：尽管治疗药物监测(TDM)已广泛应用于多个疾病治疗领域,但在抗肿瘤药物方面的应用仍较为局限。近年来,抗肿瘤药物的暴露量与其疗效和药物不良反应之间的相关性研究越来越多,这有利于抗肿瘤药物个体化精准给药。本文综述了细胞毒类和靶向性(小分子和大分子)抗肿瘤药物的治疗药物监测现状,为肿瘤药物个体化用药提供参考。Although therapeutic drug monitoring TDM) has been increasingly used in clinical practice in recent years,there are still many limitations in anticancer drugs. In the past 20 years,there are lots of studies regarding the relationship between the exposure of anticancerdrugs and clinical outcomes or adverse reactions,which promote the development of individualized treatment. This article reviews the current status of therapeutic drug monitoring of anticancer drugs including cytotoxic drugs and targeted drugs small molecules and macromolecules) and provides information for individual treatment of anticancer drugs.

关 键 词：抗肿瘤药物 治疗药物监测 血药浓度 药代动力学/药效学 

分 类 号：R979.1[医药卫生—药品]